# A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

> **NCT02975934** · PHASE3 · COMPLETED · sponsor: **pharmaand GmbH** · enrollment: 405 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** Rucaparib
- **DRUG:** Abiraterone acetate or Enzalutamide or Docetaxel

## Key facts

- **NCT ID:** NCT02975934
- **Lead sponsor:** pharmaand GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-13
- **Primary completion:** 2022-08-25
- **Final completion:** 2024-08-08
- **Target enrollment:** 405 (ACTUAL)
- **Last updated:** 2025-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02975934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02975934, "A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02975934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*